cagrisema novo nordisk news - Search News

Novo Nordisk shares plummet

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

New York Post on MSN · 17h

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

CNN on MSN · 16h

Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.

20h

Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

18h

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

20h

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...

18hon MSN

Novo Nordisk stock just tanked 25%: here’s what happened

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

13hon MSN

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results